225 related articles for article (PubMed ID: 35841169)
1. [Imeglimin: features of the mechanism of action and potential benefits].
Kuznetsov KO; Saetova AA; Mahmutova EI; Bobrik AG; Bobrik DV; Nagaev IR; Khamitova AD; Arapieva AM
Probl Endokrinol (Mosk); 2022 Mar; 68(3):57-66. PubMed ID: 35841169
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
Johansson KS; Brønden A; Knop FK; Christensen MB
Expert Opin Pharmacother; 2020 Jun; 21(8):871-882. PubMed ID: 32108532
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Hallakou-Bozec S; Vial G; Kergoat M; Fouqueray P; Bolze S; Borel AL; Fontaine E; Moller DE
Diabetes Obes Metab; 2021 Mar; 23(3):664-673. PubMed ID: 33269554
[TBL] [Abstract][Full Text] [Related]
4. Imeglimin: the New Kid on the Block.
Shrestha SC; Gupta S
Curr Diab Rep; 2024 Jan; 24(1):13-18. PubMed ID: 38051432
[TBL] [Abstract][Full Text] [Related]
5. Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Theurey P; Vial G; Fontaine E; Monternier PA; Fouqueray P; Bolze S; Moller DE; Hallakou-Bozec S
Physiol Rep; 2022 Mar; 10(5):e15151. PubMed ID: 35274817
[TBL] [Abstract][Full Text] [Related]
6. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
Pirags V; Lebovitz H; Fouqueray P
Diabetes Obes Metab; 2012 Sep; 14(9):852-8. PubMed ID: 22519919
[TBL] [Abstract][Full Text] [Related]
7. Protective Effects of Imeglimin and Metformin Combination Therapy on β-Cells in db/db Male Mice.
Nishiyama K; Ono M; Tsuno T; Inoue R; Fukunaka A; Okuyama T; Kyohara M; Togashi Y; Fukushima S; Atsumi T; Sato A; Tsurumoto A; Sakai C; Fujitani Y; Terauchi Y; Ito S; Shirakawa J
Endocrinology; 2023 Jun; 164(8):. PubMed ID: 37314160
[TBL] [Abstract][Full Text] [Related]
8. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.
Vuylsteke V; Chastain LM; Maggu GA; Brown C
Drugs R D; 2015 Sep; 15(3):227-32. PubMed ID: 26254210
[TBL] [Abstract][Full Text] [Related]
9. Imeglimin: Current Development and Future Potential in Type 2 Diabetes.
Konkwo C; Perry RJ
Drugs; 2021 Feb; 81(2):185-190. PubMed ID: 33247829
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
[TBL] [Abstract][Full Text] [Related]
11. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
[TBL] [Abstract][Full Text] [Related]
12. Imeglimin mitigates the accumulation of dysfunctional mitochondria to restore insulin secretion and suppress apoptosis of pancreatic β-cells from db/db mice.
Aoyagi K; Nishiwaki C; Nakamichi Y; Yamashita SI; Kanki T; Ohara-Imaizumi M
Sci Rep; 2024 Mar; 14(1):6178. PubMed ID: 38485716
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Fouqueray P; Pirags V; Inzucchi SE; Bailey CJ; Schernthaner G; Diamant M; Lebovitz HE
Diabetes Care; 2013 Mar; 36(3):565-8. PubMed ID: 23160726
[TBL] [Abstract][Full Text] [Related]
14. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
15. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
[TBL] [Abstract][Full Text] [Related]
16. A review of phenformin, metformin, and imeglimin.
Yendapally R; Sikazwe D; Kim SS; Ramsinghani S; Fraser-Spears R; Witte AP; La-Viola B
Drug Dev Res; 2020 Jun; 81(4):390-401. PubMed ID: 31916629
[TBL] [Abstract][Full Text] [Related]
17. The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells.
Vial G; Lamarche F; Cottet-Rousselle C; Hallakou-Bozec S; Borel AL; Fontaine E
Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00211. PubMed ID: 33855213
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
[TBL] [Abstract][Full Text] [Related]
19. Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes.
Ishibashi R; Hirayama K; Watanabe S; Okano K; Kuroda Y; Baba Y; Kanayama T; Ito C; Kasahara K; Aiba S; Iga R; Ohtani R; Inaba Y; Koshizaka M; Maezawa Y; Yokote K
J Diabetes Investig; 2023 Dec; 14(12):1419-1422. PubMed ID: 37715448
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
